These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 27401940)

  • 1. Clinical trial network for the promotion of clinical research for rare diseases in Japan: muscular dystrophy clinical trial network.
    Shimizu R; Ogata K; Tamaura A; Kimura E; Ohata M; Takeshita E; Nakamura H; Takeda S; Komaki H
    BMC Health Serv Res; 2016 Jul; 16():241. PubMed ID: 27401940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Infrastructure for the clinical research of muscular dystrophies: remudy and MDCTN].
    Kimura E; Nakamura H; Mitsuhashi S; Takeuchi F; Mori-Yoshimura M; Shimizu R; Komaki H; Hayashi YK; Nishino I; Kawai M; Takeda S
    Rinsho Shinkeigaku; 2014; 54(12):1069-70. PubMed ID: 25519964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Registry of muscular dystrophy (Remudy). Construction of the patient self-report registry and collaboration with overseas network].
    Nakamura H; Kawai M
    Rinsho Shinkeigaku; 2011 Nov; 51(11):901-2. PubMed ID: 22277410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Infrastructure for new drug development to treat muscular dystrophy: current status of patient registration (remudy)].
    Nakamura H; Kimura E; Kawai M
    Brain Nerve; 2011 Nov; 63(11):1279-84. PubMed ID: 22068481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Remudy].
    Kimura E; Nakamura H; Nishino I
    Brain Nerve; 2014 Nov; 66(11):1396-402. PubMed ID: 25407075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Establishment of an evaluation method for muscular dystrophy and a patient registration system for clinical trials].
    Kawai M
    Rinsho Shinkeigaku; 2009 Nov; 49(11):863-6. PubMed ID: 20030232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A checklist for clinical trials in rare disease: obstacles and anticipatory actions-lessons learned from the FOR-DMD trial.
    Crow RA; Hart KA; McDermott MP; Tawil R; Martens WB; Herr BE; McColl E; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Hirtz D; Lochmuller H; Straub V; Ciafaloni E; Shieh PB; Spinty S; Childs AM; Manzur AY; Morandi L; Butterfield RJ; Horrocks I; Roper H; Flanigan KM; Kuntz NL; Mah JK; Morrison L; Darras BT; von der Hagen M; Schara U; Wilichowski E; Mongini T; McDonald CM; Vita G; Barohn RJ; Finkel RS; Wicklund M; McMillan HJ; Hughes I; Pegoraro E; Bryan Burnette W; Howard JF; Thangarajh M; Campbell C; Griggs RC; Bushby K; Guglieri M
    Trials; 2018 May; 19(1):291. PubMed ID: 29793540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of Japanese Duchenne and Becker muscular dystrophy patients in a novel Japanese national registry of muscular dystrophy (Remudy).
    Nakamura H; Kimura E; Mori-Yoshimura M; Komaki H; Matsuda Y; Goto K; Hayashi YK; Nishino I; Takeda S; Kawai M
    Orphanet J Rare Dis; 2013 Apr; 8():60. PubMed ID: 23601510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Muscular Dystrophy Association's neuroMuscular ObserVational Research Data Hub (MOVR): Design, Methods, and Initial Observations.
    Kilroy EA; Burris R; Javelosa E; Waits J; Lek A; Rodgers R; Opgenorth H; Hesterlee S
    J Neuromuscul Dis; 2023; 10(3):365-380. PubMed ID: 36911943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Social difficulties and care burden of adult Duchenne muscular dystrophy in Japan: a questionnaire survey based on the Japanese Registry of Muscular Dystrophy (Remudy).
    Mori-Yoshimura M; Ishigaki K; Shimizu-Motohashi Y; Ishihara N; Unuma A; Yoshida S; Nakamura H
    Orphanet J Rare Dis; 2024 Apr; 19(1):182. PubMed ID: 38689355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient engagement in clinical trial design for rare neuromuscular disorders: impact on the DELIVER and ACHIEVE clinical trials.
    Furlong P; Dugar A; White M
    Res Involv Engagem; 2024 Jan; 10(1):1. PubMed ID: 38167117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Background, introduction and activity of the Japan Primary Registries Network.
    Shiokawa T
    J Evid Based Med; 2009 Feb; 2(1):41-3. PubMed ID: 21348982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerating Rare Disease Drug Development: Lessons Learned from Muscular Dystrophy Patient Advocacy Groups.
    Huml RA; Dawson J; Bailey M; Nakas N; Williams J; Kolochavina M; Huml JR
    Ther Innov Regul Sci; 2021 Mar; 55(2):370-377. PubMed ID: 32974874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Barriers and facilitators to clinical trial participation among parents of children with pediatric neuromuscular disorders.
    Peay HL; Biesecker BB; Wilfond BS; Jarecki J; Umstead KL; Escolar DM; Tibben A
    Clin Trials; 2018 Apr; 15(2):139-148. PubMed ID: 29475375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Muscular Dystrophy Surveillance, Tracking, and Research Network pilot: Population-based surveillance of major muscular dystrophies at four U.S. sites, 2007-2011.
    Do TN; Street N; Donnelly J; Adams MM; Cunniff C; Fox DJ; Weinert RO; Oleszek J; Romitti PA; Westfield CP; Bolen J;
    Birth Defects Res; 2018 Nov; 110(19):1404-1411. PubMed ID: 30070776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The TREAT-NMD Duchenne muscular dystrophy registries: conception, design, and utilization by industry and academia.
    Bladen CL; Rafferty K; Straub V; Monges S; Moresco A; Dawkins H; Roy A; Chamova T; Guergueltcheva V; Korngut L; Campbell C; Dai Y; Barišić N; Kos T; Brabec P; Rahbek J; Lahdetie J; Tuffery-Giraud S; Claustres M; Leturcq F; Ben Yaou R; Walter MC; Schreiber O; Karcagi V; Herczegfalvi A; Viswanathan V; Bayat F; de la Caridad Guerrero Sarmiento I; Ambrosini A; Ceradini F; Kimura E; van den Bergen JC; Rodrigues M; Roxburgh R; Lusakowska A; Oliveira J; Santos R; Neagu E; Butoianu N; Artemieva S; Rasic VM; Posada M; Palau F; Lindvall B; Bloetzer C; Karaduman A; Topaloğlu H; Inal S; Oflazer P; Stringer A; Shatillo AV; Martin AS; Peay H; Flanigan KM; Salgado D; von Rekowski B; Lynn S; Heslop E; Gainotti S; Taruscio D; Kirschner J; Verschuuren J; Bushby K; Béroud C; Lochmüller H
    Hum Mutat; 2013 Nov; 34(11):1449-57. PubMed ID: 23913485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duchenne muscular dystrophy: clinical trials and emerging tribulations.
    Shieh PB
    Curr Opin Neurol; 2015 Oct; 28(5):542-6. PubMed ID: 26280938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular therapies: present and future in neuromuscular diseases].
    Ziegler A; Walter MC; Schoser BE
    Nervenarzt; 2023 Jun; 94(6):473-487. PubMed ID: 37221259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology of progressive muscular dystrophy in Okinawa, Japan. Classification with molecular biological techniques.
    Nakagawa M; Nakahara K; Yoshidome H; Suehara M; Higuchi I; Fujiyama J; Nakamura A; Kubota R; Takenaga S; Arahata K
    Neuroepidemiology; 1991; 10(4):185-91. PubMed ID: 1745328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engaging Participants in Rare Disease Research: A Qualitative Study of Duchenne Muscular Dystrophy.
    Bendixen RM; Morgenroth LP; Clinard KL
    Clin Ther; 2016 Jun; 38(6):1474-1484.e2. PubMed ID: 27136712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.